Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NXPmTXBSOjV7NkCyPFI>
KellyCis83 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PjVmlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= NHr5eY4zPTl4MEK4Ni=>
SK-N-AS NWDqOmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PyOGlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= MWqyOVk3ODJ6Mh?=
SK-N-ASCis24 NF;MXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjuTWM2OD1yLkW35qCKyrIkgJmwMlEyKM7:TR?= MmXJNlU6PjB{OEK=
U87 NVTHe414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljONE02OCEQvF2= M17OVlQ5KGh? NWLuRYc1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= MoDyNlU4PTB{N{O=
HCT116 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ls[FAvPS1{LkWg{txO Ml\ZOFjDqGkEoB?= MnKzTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NIPUZVIzPTd2Nke2Ny=>
HT-29 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnRNE42NTJwNTFOwG0> NYjvOZY1PDkEoHlCpC=> MoXGTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? M{PKflI2PzR4N{[z
Caco2 NHHXUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCNE42NTJwNTFOwG0> NXfrbWN5PDkEoHlCpC=> MUTJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? NV3EbFZTOjV5NE[3OlM>
COLO 205 NWPCWW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPJfINYOC53LUKuOUDPxE1? MYK0POKhcMLi MnyxTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP MoTRNlU4PDZ5NkO=
SW480 M1HWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWwMlUuOi53IN88US=> MUO0POKhcMLi NWLYbnQ5UUN3ME20MlkzyqEEsdMgNE4{O8LizszN NHTZVHUzPTd2Nke2Ny=>
HEK293T NUjITHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG3bXIyNTVizszN MonrOFjDqGkEoB?= MV\JR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? NH3GPWgzPTd2Nke2Ny=>
Hep3B  NEjqWJBHfW6ldHnvckBCe3OjeR?= NFrCdWUyOCEQvF2= M2rFWFQ5yqCqwrC= NEH0Vmdz\WS3Y3XzJJRp\SCnbnjhcoNqdmdiZX\m[YN1KG:oIFLNVE03 MoS0NlU3OzN3NkS=
Hep3B  M4PmVWZ2dmO2aX;uJGF{e2G7 MW[wMlEuOTBizszN M2\Yb|I1KGh? NYqzVYVZe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B M37wOVI2PjN|NU[0
HEK293 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPtSVVKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= MWiyOVYxOzF{Mh?=
DU145 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXWPI5XUUN3ME2yMlI5yqEEsdMgNE4xPMLizszN M4Xqc|I2PjB|MUKy
HCT15 NFO0dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjnc|NKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MnjUNlU3ODNzMkK=
T47D M3nqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1VWR2UUN3ME2zMlE5yqEEsdMgNE4yOcLizszN MkDINlU3ODNzMkK=
SMMC-7721 NWnYS|ByTnWwY4Tpc44hSXO|YYm= MlnGOFAh|ryP MYm0PEBp MXfEUXNQ NIrmcJJqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? NGO1O2czPTV2NEO2NS=>
MDA-MB-231 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7GOWJWPzMEoHi= NWq5R5RVUUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= NUnjcGZ7OjV2OE[yNVk>
MCF-7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nnZ|czyqCq M4PnVmlEPTB;MUCuPeKhyrIEoEKuNeKh|ryP M4XUPFI2PDh4MkG5
Jurkat NEfMeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NuKhcA>? Mk\CTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? Mm\BNlU1QDZ{MUm=
HeLa MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LVSVczyqCq MXjJR|UxRTNwOdMgxtHDqDJwM9Mg{txO NXfqXJpXOjV2OE[yNVk>
MCF7  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL0N2tVPS1zMECg{txO NF\pXGg4KGR? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYGyOVQ4OjZzOR?=
K562 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NuKhcA>? NFzaUG5KSzVyPUCuNlnDqM7:TR?= NXu5c|dIOjV{OEK2OVM>
K/VP.5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn3O|LDqGh? MXPJR|UxRTRwOdMg{txO MVWyOVI5OjZ3Mx?=
SH-EP  NFTOOohHfW6ldHnvckBCe3OjeR?= NWrw[|htOjEEoN88[{9udA>? NXviZ4tUOjUEoHi= M3PRXIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= NETP[5YzPTJ4MUm4NS=>
SCC25 NWOzSGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\DZ|I1yqCq MkC0TWM2OD12Mz6zxsDDucLiMT6xNuKh|ryP NWqxU2hnOjV{MkC3Nlk>
CAL27 M3Twdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7yWXMzPMLiaB?= MlPyTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NGP1SlkzPTJ{MEeyPS=>
FaDu MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSyUFk2OjUEoHi= MnPRTWM2OD1{NT64PeKhyrIEoEGuNVPDqM7:TR?= NYK4e|U6OjV{MkC3Nlk>
SCC25 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTzb4o1QMLiaB?= MX3JR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP NVnhNHMxOjV{MkC3Nlk>
CAL27 M3u0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTNT48{PDkEoHi= MYjJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP M17DVVI2OjJyN{K5
FaDu NVzo[nFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrFbXE1QMLiaB?= NHzQ[lRKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= M4m1OFI2OjJyN{K5
SCC25 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfiWI41PzMEoHi= MmjSTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP M3XXW|I2OjJyN{K5
CAL27 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDmTHk4OsLiaB?= MUXJR|UxRTRwMkhCpOKyyqBzLkG0xsDPxE1? NVvOd49{OjV{MkC3Nlk>
FaDu MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\OVVczyqCq MojVTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP Ml3TNlUzOjB5Mkm=
MCF-7 M2i1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLqOFjDqGkEoB?= MWHEUXNQ NUjKdFYyUUN3ME23MlLDqMLzwrCwMljDqM7:TR?= NV;uSm9jOjV{MU[zO|g>
T-47D NHGxNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWi0POKhcMLi NXv5eJQxTE2VTx?= MoLaTWM2OD15LkhCpOKyyqByLkhCpO69VQ>? MmPUNlUzOTZ|N{i=
MDA-MB-231 M4LrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHqcGg1QMLiaNMg M3TU[mROW09? MWDJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? Mlj1NlUzOTZ|N{i=
DU145 MV7BdI9xfG:|aYOgRZN{[Xl? Mm\nNVAuOTByIN88US=> M{S3UVghcA>? NEO0dJlFVVOR MV\pcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? MkXpNlUyPDl4OEG=
DU145 stem-like MoD0RZBweHSxc3nzJGF{e2G7 MXexNE0yODBizszN M1PmclghcA>? NX:xWJF6TE2VTx?= MoXTbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIi0dVUzPTF2OU[4NS=>
DU145 M{PFNWZ2dmO2aX;uJGF{e2G7 MVqxNE0yODBizszN NHLrTJozKGh? MofRSG1UVw>? M3LjUolv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGTIdJMzPTF2OU[4NS=>
DU145 stem-like MW\GeY5kfGmxbjDBd5NigQ>? NF\0VogyOC1zMECg{txO NFzPOnczKGh? NF;6WolFVVOR NETXRVNqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIfxd5czPTF2OU[4NS=>
UW228-3 NYSydmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKwMlAyNTNyMDFOwG0> NEPH[I01QCCq MUnEUXNQ NYO4WWFLUUN3ME2wMlk6yqEQvF2= NUjEd4hmOjVzMUmxPFU>
NSCs NIjtfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLoNE4xOS1|MECg{txO M37ENFQ5KGh? M1Lm[WROW09? M1PYZWlEPTB;MD6zMVPDqM7:TR?= NV[wNoN{OjVzMUmxPFU>
MKL-1  M{\DSGZ2dmO2aX;uJGF{e2G7 NF3sNZIyOC1zMECwJI5O NXPscpV7PCCm NIm3UIlqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= NHS2VWQzPTFzNke1OC=>
MCF7 EV M{XFTmZ2dmO2aX;uJGF{e2G7 NXfjTGxqOTBvMUCwJO69VQ>? NX23dFUyOuLCiXi= M2\SZolv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ NEPpPFczPTB6OEKwNy=>
MCF 7BMI1 MnO0SpVv[3Srb36gRZN{[Xl? M{DxU|ExNTFyMDFOwG0> NUTyNpY2OuLCiXi= NWmwcplGcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? MXiyOVA5QDJyMx?=
MCF7 EV M1O0N2Z2dmO2aX;uJGF{e2G7 M{jxdFExNTFyMDFOwG0> NEjBOoMz6oDLaB?= NUCzeFFiTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NVm4S|hYOjVyOEiyNFM>
MCF7 BMI1 M3vmb2Z2dmO2aX;uJGF{e2G7 NYntbHJWOTBvMUCwJO69VQ>? M2HKflLjiImq MnzhSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NXHHPItwOjVyOEiyNFM>
HepG2 NWHVfWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq0fVVFVVORwrC= NWTJWnRMUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> MYWyOVA4QDNzMR?=
MOLT-3 NVrmWHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUezT3JNTE2VT9Mg NILmcWhKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> M2PhU|I2ODd6M{Gx
HT1080 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyxMVExOCEQvF2= MXu0M|I1NzR6IHi= M2W2XmROW00EoB?= M3HnXolv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MUCyOVA4QDB4NB?=
HT1080 MnjwSpVv[3Srb36gRZN{[Xl? MUmwMlAxODFvMUCwJO69VQ>? MmTmNU0zPCCq NIHwe5NFVVORwrC= NGW0b4lqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NVzMeJNNOjVyN{iwOlQ>
HT1080 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jKZlAvODByMT2xNFAh|ryP M1OzTVI1KGh? NE\ITYxFVVORwrC= NGDUenpk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz NHPnO2MzPTB5OEC2OC=>
HD-MY-Z MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjRNlQwPDhxN{KgbC=> M3HBeWlEPTExvK6xNFAh|ryP NWDKfoc3OjVyNEiyN|Y>
DOHH-2 M2jwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;2ZlI1KGh? MWTJR|Ux97zgMUCwJO69VQ>? M2fJbFI2ODR6MkO2
DOHH-2 NHHRbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P2dlQ5KGh? NGjr[GtKSzVyPUG5MlnDqM7:TR?= MWqyOVA1QDJ|Nh?=
DOHH-2 M{HGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLhO|IhcA>? Mn\aTWM2OD13wrFOwG0> MWGyOVA1QDJ|Nh?=
REH NIHZOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWxNlQhcA>? M1zvemlEPTB;MD6wNlfDqM7:TR?= NEP2SpQzPTB2OEKzOi=>
REH M361Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDIT45tPDhiaB?= MVTJR|UxRTBwMEG0xsDPxE1? NFXkW4szPTB2OEKzOi=>
REH MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hw[FczKGh? M2fHRWlEPTB;MD6wNVXDqM7:TR?= NVrFeFZbOjVyNEiyN|Y>
HH NUjNWIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPBNlQhcA>? MWPJR|UxRTFyND63xsDPxE1? NX;1UWt6OjVyNEiyN|Y>
HH M2q1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPlOFghcA>? NHPre3BKSzVyPUS4MlbDqM7:TR?= MXmyOVA1QDJ|Nh?=
HH Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHvN5JlPzJiaB?= MnHsTWM2OD1zND63xsDPxE1? MU[yOVA1QDJ|Nh?=
HuT-78 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmyOEBp NWrSV4lYUUN3ME25MlPDqM7:TR?= NG\tRpYzPTB2OEKzOi=>
HuT-78 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L1fVQ5KGh? MYLJR|UxRTRwM9Mg{txO NED3fIMzPTB2OEKzOi=>
HuT-78 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDsO|IhcA>? M1K5b2lEPTB;ND6yxsDPxE1? M3jZcFI2ODR6MkO2
OPM-2 M{nRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDpSIczPCCq NFXCWG9KSzVyPUK0MlHDqM7:TR?= MXuyOVA1QDJ|Nh?=
OPM-2 NX7Pc4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPDOFghcA>? NXvQ[oxZUUN3ME20xsDPxE1? M2Szb|I2ODR6MkO2
OPM-2 NHvvdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW3T|M4OiCq NEXiN5NKSzVyPUGuN:Kh|ryP NFnDVnczPTB2OEKzOi=>
RPMI-8226 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTzNlQhcA>? MYnJR|UxRTFyNj62xsDPxE1? NUfZbGZ[OjVyNEiyN|Y>
RPMI-8226 NUfNeYFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnXZpo1QCCq NWf6Xm57UUN3ME25NU4yyqEQvF2= M3TS[VI2ODR6MkO2
RPMI-8226 NInPeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jaWVczKGh? M2PTd2lEPTB;MUSuPeKh|ryP M3;ZUlI2ODR6MkO2
U-266 M1XpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n2TlI1KGh? NFXTb5RKSzVyPUi2MlLDqM7:TR?= NHrjdFgzPTB2OEKzOi=>
U-266 NW\WR5pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vFb|Q5KGh? MWPJR|UxRTZ6LkVCpO69VQ>? NFPURXUzPTB2OEKzOi=>
U-266 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVS3NkBp M3m5OGlEPTB;MkeuOOKh|ryP M{X6R|I2ODR6MkO2
Kelly NEfVUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BNE0yOCEQvF2= NUXJO4dGPzMEoHi= MkToTWM2OD1zLkWxPOKh|ryP NHn1cFAzPTByOEmwNC=>
SH-SY5Y  M2f3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMVExKM7:TR?= NH7sUJA4OsLiaB?= MkTSTWM2OD1yLke1OOKh|ryPwrC= MUKyOVAxQDlyMB?=
SK-N-AS MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\FOlAuOTBizszN NInBRVA4OsLiaB?= M4jhT2lEPTB;MT63NVLDqM7:TdMg MmP6NlUxODh7MEC=
SK-N-DZ M1X2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMVExKM7:TR?= MYK3NuKhcA>? NFHid5BKSzVyPUWuOFg2yqEQvF2= NIjKSnozPTByOEmwNC=>
HepG2 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG0POKhcA>? NH;wWYhFVVORwrC= NX;IXJFVUUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> MX2yOFk6PjF|Nh?=
A549 NGrodGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjl[3A1QMLiaB?= NFnVWGhFVVORwrC= MX;JR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NHvrVnMzPDl7NkGzOi=>
MCF7 NFLN[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17HT|Q5yqCq M4[1PGROW00EoB?= M3TuTmlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN NEjXR3AzPDl7NkGzOi=>
HL-60  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3NuKhcA>? NUPnV|Z5UUN3ME2wMlEz6oDHzszN NIDWT2MzPDl7M{CxOC=>
HL-60[R] NV3rT4lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe3NuKhcA>? NYLM[pVJUUN3ME2zMlEz6oDHzszN NELZcpEzPDl7M{CxOC=>
MIAPACA NGjNW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPYUJE6T0l3ME2xMlMhyrFiMD6wN{DPxE1? MVmyOFk2Ozh{MR?=
MCF-7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXMSFBIUTVyPUCuNlUhyrFiMD6xJO69VQ>? M4fDNVI1QTV|OEKx
HeLa NHLyXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfrOIJIUTVyPUCuOlQhyrFiMD60JO69VQ>? MlTrNlQ6PTN6MkG=
MO59K  NVjkZ2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDvU5RQPyCm NIHHO|RKSzVyPUCuNVfjiIYQvF2= NVHCN5FKOjR7NUO1OlE>
MO59J NFixcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13DNlch\A>? NY\NXWQxUUN3ME2wMlHjiIYQvF2= NGqxe4MzPDl3M{W2NS=>
ME 180 NEPpVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHlOFjDqGkEoB?= NFrTW2VKSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= M4TZZlI1QTV|MEK3
MCF-7 M{XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq0POKhcMLi MmjXTWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? NEfoclYzPDl3M{CyOy=>
HeLa MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy0POKhcMLi NFLRRnVKSzVyPUSuO|EhyrFiMT605qCG|ryP NH\ie3IzPDl3M{CyOy=>
MDA-MB-453 NGHyTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjMOpVTPDkEoHlCpC=> NUX6Tm1vUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= M2rzO|I1QTV|MEK3
MDA-MB-231 M1LYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjR[IFkPDkEoHlCpC=> M2nuS2lEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= M1f4NFI1QTV|MEK3
PC-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC0POKhcMLi MXHJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? NYXHcItzOjR7NUOwNlc>
HT-29 NU\YVFV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnQb|E1QMLiaNMg M3rrRmlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= MmjwNlQ6PTNyMke=
BGC-823 NHz1cpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS4OoQ1QMLiaNMg MlTDTWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP NG\YbVIzPDd7M{i3Oy=>
HeLa MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUK0POKhcMLi MkfxTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN NFnD[4MzPDd7M{i3Oy=>
A549 NVfDXYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0WFQ5yqCqwrC= NYH0bnBUUUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> NEXoZlMzPDd7M{i3Oy=>
HK-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDKbHNrPDkEoHlCpC=> NVn4Nm15UUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= MmLrNlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03583424 Recruiting Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) July 9 2018 Phase 1|Phase 2
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT01458366 Active not recruiting Non-Hodgkin''s Lymphoma Sidney Kimmel Cancer Center at Thomas Jefferson University|GlaxoSmithKline|Novartis|Thomas Jefferson University November 9 2011 Phase 1|Phase 2
NCT03016871 Recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|TNFRSF8 Positive City of Hope Medical Center|National Cancer Institute (NCI) May 8 2017 Phase 2
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT02070458 Active not recruiting Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia Case Comprehensive Cancer Center|National Cancer Institute (NCI) October 8 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID